GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Cyclically Adjusted PS Ratio

Xvivo Perfusion AB (Xvivo Perfusion AB) Cyclically Adjusted PS Ratio : 37.09 (As of May. 17, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Cyclically Adjusted PS Ratio?

As of today (2024-05-17), Xvivo Perfusion AB's current share price is $37.09. Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.00. Xvivo Perfusion AB's Cyclically Adjusted PS Ratio for today is 37.09.

The historical rank and industry rank for Xvivo Perfusion AB's Cyclically Adjusted PS Ratio or its related term are showing as below:

XVIPF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 17.63   Med: 28.83   Max: 36.28
Current: 36.28

During the past years, Xvivo Perfusion AB's highest Cyclically Adjusted PS Ratio was 36.28. The lowest was 17.63. And the median was 28.83.

XVIPF's Cyclically Adjusted PS Ratio is ranked worse than
97.89% of 474 companies
in the Medical Devices & Instruments industry
Industry Median: 2.185 vs XVIPF: 36.28

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xvivo Perfusion AB's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.567. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.00 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xvivo Perfusion AB Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Cyclically Adjusted PS Ratio Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 22.31 32.76

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.34 33.04 28.54 32.76 26.12

Competitive Comparison of Xvivo Perfusion AB's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted PS Ratio falls into.



Xvivo Perfusion AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Xvivo Perfusion AB's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=37.09/1
=37.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Xvivo Perfusion AB's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.567/132.2054*132.2054
=0.567

Current CPI (Mar. 2024) = 132.2054.

Xvivo Perfusion AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.140 100.432 0.184
201409 0.145 100.161 0.191
201412 0.154 100.225 0.203
201503 0.172 99.950 0.228
201506 0.164 99.995 0.217
201509 0.148 100.228 0.195
201512 0.177 100.276 0.233
201603 0.187 100.751 0.245
201606 0.193 101.019 0.253
201609 0.156 101.138 0.204
201612 0.179 102.022 0.232
201703 0.176 102.022 0.228
201706 0.163 102.752 0.210
201709 0.153 103.279 0.196
201712 0.188 103.793 0.239
201803 0.197 103.962 0.251
201806 0.199 104.875 0.251
201809 0.171 105.679 0.214
201812 0.245 105.912 0.306
201903 0.192 105.886 0.240
201906 0.223 106.742 0.276
201909 0.208 107.214 0.256
201912 0.248 107.766 0.304
202003 0.177 106.563 0.220
202006 0.123 107.498 0.151
202009 0.167 107.635 0.205
202012 0.251 108.296 0.306
202103 0.232 108.360 0.283
202106 0.243 108.928 0.295
202109 0.218 110.338 0.261
202112 0.323 112.486 0.380
202203 0.324 114.825 0.373
202206 0.318 118.384 0.355
202209 0.301 122.296 0.325
202212 0.428 126.365 0.448
202303 0.450 127.042 0.468
202306 0.480 129.407 0.490
202309 0.439 130.224 0.446
202312 0.507 131.912 0.508
202403 0.567 132.205 0.567

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xvivo Perfusion AB  (OTCPK:XVIPF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Xvivo Perfusion AB Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.